Target Price | €49.93 |
Price | €53.46 |
Deviation | 6.60% |
Number of Estimates | 19 |
19 Analysts have issued a price target Fresenius Medical Care 2026 . The average Fresenius Medical Care target price is €49.93. This is 6.60% lower than the current stock price. The highest price target is €60.00 12.23% , the lowest is €37.00 30.79% . | |
A rating was issued by 22 analysts: 8 Analysts recommend Fresenius Medical Care to buy, 9 to hold and 5 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Fresenius Medical Care stock has an average upside potential 2026 of 6.60% . Most analysts recommend the Fresenius Medical Care stock at Hold. |
17 Analysts have issued a sales forecast Fresenius Medical Care 2025 . The average Fresenius Medical Care sales estimate is €19.7b . This is 1.02% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €20.1b 2.86% , the lowest is €19.3b 0.79% .
This results in the following potential growth metrics:
2024 | €19.3b | 0.61% |
---|---|---|
2025 | €19.7b | 1.84% |
2026 | €20.4b | 3.53% |
2027 | €21.2b | 3.85% |
2028 | €22.1b | 4.22% |
2029 | €23.0b | 4.41% |
15 Analysts have issued an Fresenius Medical Care EBITDA forecast 2025. The average Fresenius Medical Care EBITDA estimate is €3.8b . This is 27.45% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €3.9b 32.80% , the lowest is €3.6b 22.07% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €3.0b | 0.73% |
---|---|---|
2025 | €3.8b | 25.19% |
2026 | €3.9b | 3.57% |
2027 | €4.1b | 5.09% |
2028 | €4.2b | 2.06% |
2029 | €4.0b | 5.33% |
2024 | 15.56% | 0.12% |
---|---|---|
2025 | 19.12% | 22.90% |
2026 | 19.13% | 0.05% |
2027 | 19.36% | 1.20% |
2028 | 18.96% | 2.07% |
2029 | 17.19% | 9.34% |
14 Fresenius Medical Care Analysts have issued a net profit forecast 2025. The average Fresenius Medical Care net profit estimate is €953m . This is 53.93% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €1.1b 78.20% , the lowest is €838m 35.35% .
This results in the following potential growth metrics and future Net Margins:
2024 | €537m | 7.65% |
---|---|---|
2025 | €953m | 77.49% |
2026 | €1.2b | 22.04% |
2027 | €1.3b | 9.74% |
2028 | €1.6b | 22.33% |
2029 | €1.5b | 3.77% |
2024 | 2.78% | 8.30% |
---|---|---|
2025 | 4.84% | 74.29% |
2026 | 5.70% | 17.77% |
2027 | 6.03% | 5.79% |
2028 | 7.08% | 17.41% |
2029 | 6.52% | 7.91% |
14 Analysts have issued a Fresenius Medical Care forecast for earnings per share. The average Fresenius Medical Care EPS is €3.25 . This is 54.03% higher than earnings per share in the financial year 2024. The highest EPS forecast is €3.76 78.20% , the lowest is €2.86 35.55% .
This results in the following potential growth metrics and future valuations:
2024 | €1.83 | 7.65% |
---|---|---|
2025 | €3.25 | 77.60% |
2026 | €3.96 | 21.85% |
2027 | €4.35 | 9.85% |
2028 | €5.32 | 22.30% |
2029 | €5.12 | 3.76% |
Current | 25.34 | 3.32% |
---|---|---|
2025 | 16.46 | 35.03% |
2026 | 13.49 | 18.04% |
2027 | 12.29 | 8.90% |
2028 | 10.05 | 18.23% |
2029 | 10.44 | 3.88% |
Based on analysts' sales estimates for 2025, the Fresenius Medical Care stock is valued at an EV/Sales of 1.27 and an P/S ratio of 0.80 .
This results in the following potential growth metrics and future valuations:
Current | 1.29 | 4.88% |
---|---|---|
2025 | 1.27 | 1.27% |
2026 | 1.23 | 3.41% |
2027 | 1.18 | 3.71% |
2028 | 1.14 | 4.04% |
2029 | 1.09 | 4.22% |
Current | 0.81 | 32.50% |
---|---|---|
2025 | 0.80 | 1.00% |
2026 | 0.77 | 3.41% |
2027 | 0.74 | 3.72% |
2028 | 0.71 | 4.05% |
2029 | 0.68 | 4.22% |
Fresenius Medical Care...
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
HSBC |
Hold
➜
Buy
|
Upgrade | Mar 23 2025 |
JEFFERIES |
Underperform
➜
Underperform
|
Unchanged | Mar 20 2025 |
METZLER EQUITIES |
Buy
➜
Buy
|
Unchanged | Feb 27 2025 |
WARBURG RESEARCH GMBH |
Sell
➜
Hold
|
Upgrade | Feb 26 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Hold
➜
Hold
|
Unchanged | Feb 25 2025 |
ODDO BHF |
Buy
➜
Buy
|
Unchanged | Feb 24 2025 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
Upgrade
HSBC:
Hold
➜
Buy
|
Mar 23 2025 |
Unchanged
JEFFERIES:
Underperform
➜
Underperform
|
Mar 20 2025 |
Unchanged
METZLER EQUITIES:
Buy
➜
Buy
|
Feb 27 2025 |
Upgrade
WARBURG RESEARCH GMBH:
Sell
➜
Hold
|
Feb 26 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
➜
Hold
|
Feb 25 2025 |
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Feb 24 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.